Pathology Beyond 2025: Lessons from the US Market

Pathology is essential in modern healthcare. The healthcare system relies on pathology to ensure patients get correct diagnosis and management. 

Today’s Australian pathology market, however, faces pressure from all sides, with stagnant MBS fees, rising collection centre rents, and limited room for consolidation. Without intervention the impact of stagnant rebates and rising costs will be pushed on to patients and reduce equity for a critical service. 

Meanwhile, the US market has seen significant changes, where leading competitors who are embracing technology, strategic M&A and diversified businesses have grown rapidly in the post-COVID era. 

We examined the top 4 US players (Quest, Labcorp, Sonic, Opco) and their strategic efforts over the last 5 years to establish potential insights and lessons learned for Australian pathology operators as archetype and competitive positioning becomes established over the next 5 years to address similar trends. 

Download our insights pack here: